Cargando…

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis. Dysregulation of the epigenetic machinery is a significant contributor to disease development. Some AML patients benefit from treatment with hypomethylating agents (HMAs), but no predictive biomarkers for ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmutz, Maximilian, Zucknick, Manuela, Schlenk, Richard F., Mertens, Daniel, Benner, Axel, Weichenhan, Dieter, Mücke, Oliver, Döhner, Konstanze, Plass, Christoph, Bullinger, Lars, Claus, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601277/ https://www.ncbi.nlm.nih.gov/pubmed/37885041 http://dx.doi.org/10.1186/s13148-023-01580-z

Ejemplares similares

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT
por: Bohl, S, et al.
Publicado: (2016)

Epigenetic Upregulation of lncRNAs at 13q14.3 in Leukemia Is Linked to the In Cis Downregulation of a Gene Cluster That Targets NF-kB
por: Garding, Angela, et al.
Publicado: (2013)

SEURAT: Visual analytics for the integrated analysis of microarray data
por: Gribov, Alexander, et al.
Publicado: (2010)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
por: Heidel, Florian H., et al.
Publicado: (2013)

Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML
por: Dubois, Alix, et al.
Publicado: (2020)

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial
por: Jahn, Nikolaus, et al.
Publicado: (2022)

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers
por: Lueck, Sonja C., et al.
Publicado: (2016)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling
por: Hieke, Stefanie, et al.
Publicado: (2016)

Prospective Randomization Trial of G-CSF-Primed Induction Regimen versus Standard Regimen in Patients with AML
por: Lee, Yoo Jin, et al.
Publicado: (2011)

Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome
por: Stomper, Julia, et al.
Publicado: (2019)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Early aberrant DNA methylation events in a mouse model of acute myeloid leukemia
por: Sonnet, Miriam, et al.
Publicado: (2014)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

P582: AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS
por: Pan, Hong, et al.
Publicado: (2023)

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

The AML-associated K313 mutation enhances C/EBPα activity by leading to C/EBPα overexpression
por: Gentle, Ian Edward, et al.
Publicado: (2021)

Assessment and optimisation of normalisation methods for dual-colour antibody microarrays
por: Sill, Martin, et al.
Publicado: (2010)

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)
por: Agrawal, Mridul, et al.
Publicado: (2019)

Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
por: Jakobsen, Janus S., et al.
Publicado: (2019)

Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol
por: Šimoničová, Kristína, et al.
Publicado: (2023)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
por: Heitmann, Jonas S., et al.
Publicado: (2023)

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
por: Gaidzik, Verena I., et al.
Publicado: (2023)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia
por: Hirsch, Susanne, et al.
Publicado: (2017)

Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
por: Halik, Adriane, et al.
Publicado: (2022)

AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
por: Klever, Marius-Konstantin, et al.
Publicado: (2023)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
por: Li, Jing, et al.
Publicado: (2023)

P416: DNA METHYLATION-BASED CHARACTERIZATION OF ACUTE MYELOID LEUKEMIA POINTS TOWARDS KDM3B AS A 5Q HAPLOINSUFFICIENCY CANDIDATE
por: Kelly, Katherine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2o9b6dum395jskttrnnt1jd96f